Under the terms of the research and development agreement

Reference no: EM13597827

Direct Drugs Inc. is planning to acquire SolvGen Inc. (SolvGen or the Company), a publicly owned company, during the fourth quarter of fiscal year ending December 31, 2006. Direct has engaged our audit engagement team to perform due diligence procedures, with an emphasis on the review of two separate material agreements: (1) a research and development agreement and (2) a license and distribution agreement, both executed by SolvGen during the first quarter of fiscal year 2006. Direct's management provided the engagement team with the following memo describing the Company's revenue recognition policy:

To: Audit Engagement Team
From: CFO, SolvGen Inc.
Subject: Revenue Recognition for Research and Development and License and
Distribution Agreements
Date: November 30, 2006

SolvGen Inc., an SEC registrant, is a pharmaceutical development company. SolvGen entered into a five-year research and development agreement with Careway Pharma Inc. on January 1, 2006. The research and development agreement calls for SolvGen to use its best efforts to further develop proprietary instrument systems that have been under development for nearly 18 months and are expected to be ready for commercial launch in the near future. In connection with executing the research and development arrangement, SolvGen and Careway also entered into a five-year license and distribution agreement dated January 1, 2006.

Under the terms of the research and development agreement, SolvGen retains all intellectual rights to the results of the research and development agreement. In connection with this agreement, SolvGen is entitled to the following nonrefundable milestone payments from Careway:

1. Exclusive negotiation payment - $1 million (paid December 1, 2005).
2. Contract signing payment - $2 million (paid January 1, 2006).
3. Commercial launch of instrument system Version 1 - $5 million (paid March 31, 2006, upon commercial launch of the instrument system).
4. Commercial launch of instrument system Version 2 - $5 million (not yet paid).
5. Commercial launch of instrument system Version 3 - $5 million (not yet paid).

Under the five-year license and distribution agreement, Careway will have the right to market and distribute the proprietary instrument systems. The license and distribution agreement requires Careway to pay SolvGen for each proprietary instrument system as it is purchased by Careway.

In accounting for the research and development and the license and distribution agreements, SolvGen recognizes the nonrefundable milestone payments when the payments are received over the remaining estimated contractual life of the agreements.

Required:
In deciding how to account for the research and development and the license and distribution agreements, address the following issues:
• What are the deliverables for the arrangement described in the case study above?
• When should the milestone payments received to date by SolvGen be recognized as revenue?
• Would your answer to the first requirement change under IFRSs? Explain your rationale supported by the guidance.
• Provide FASB number and IFRS number that applies or supports each question.

Reference no: EM13597827

Questions Cloud

Wat would you do as controller for the firm do you have a : you are controller for an architectural firm whose accounting year ends on december 21. as par of the management team

Kern company sells merchandise on account for 6000 to block : kern company sells merchandise on account for 6000 to block company with credit terms of 210 n30. block company

Fogelberg company purchased equipment for 12000 sales tax : fogelberg company purchased equipment for 12000. sales tax on the purchase was 600. other costs incurred were freight

How does the fifo method differ from the average costing : how does the fifo method differ from the average costing method of process costing system? provide an example of fifo

Under the terms of the research and development agreement : direct drugs inc. is planning to acquire solvgen inc. solvgen or the company a publicly owned company during the fourth

Compute the flexible-budget variances for the following two : four flags is a retail department store. on january 1 2011 four flags accountants used the following data to develop

Assuming that the perpetual inventory method is used and : inventory information for part 311 of seminole corp. discloses the following information for the month of june.june 1

Past experience has shown that the ending inventory for : past experience has shown that the ending inventory for each month should be equal to 10 of the next months sales in

The types of decision are that should be transfered to the : the types of decision are that should be transfered to the new divisional managing directors if such reogranization is

User Account

All Pages